Novozymes 将来の成長

Future 基準チェック /36

Novozymes利益と収益がそれぞれ年間19.5%と12.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に8.1% 11.4%なると予測されています。

主要情報

19.5%

収益成長率

11.4%

EPS成長率

Chemicals 収益成長	52.3%
収益成長率	12.3%
将来の株主資本利益率	8.1%
アナリストカバレッジ	Good
最終更新日	09 Apr 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:NSIS N - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	33,658	6,486	6,373	9,589	7
12/31/2025	31,457	5,531	5,222	8,381	7
12/31/2024	29,428	4,245	4,061	6,573	7
12/31/2023	17,899	3,024	2,097	4,152	N/A
9/30/2023	17,825	3,209	1,263	3,614	N/A
6/30/2023	17,736	3,425	616	3,248	N/A
3/31/2023	17,805	3,628	618	3,545	N/A
12/31/2022	17,553	3,676	1,116	4,006	N/A
9/30/2022	16,858	3,418	1,528	4,117	N/A
6/30/2022	16,252	3,108	1,946	4,007	N/A
3/31/2022	15,546	3,093	2,504	3,939	N/A
12/31/2021	14,951	3,146	2,822	4,062	N/A
9/30/2021	14,563	3,175	3,428	4,413	N/A
6/30/2021	14,233	3,044	3,209	4,197	N/A
3/31/2021	14,002	2,895	3,293	4,290	N/A
12/31/2020	14,012	2,825	3,415	4,355	N/A
9/30/2020	14,297	3,093	3,294	3,881	N/A
6/30/2020	14,570	3,020	3,463	3,997	N/A
3/31/2020	14,679	3,273	3,035	3,596	N/A
12/31/2019	14,374	3,154	2,629	3,196	N/A
9/30/2019	14,357	3,069	2,358	3,436	N/A
6/30/2019	14,311	3,238	2,616	3,768	N/A
3/31/2019	14,351	3,116	2,305	3,558	N/A
12/31/2018	14,390	3,226	2,287	3,679	N/A
9/30/2018	14,349	3,183	2,258	3,839	N/A
6/30/2018	14,271	3,194	1,954	3,649	N/A
3/31/2018	14,311	3,154	2,048	3,738	N/A
12/31/2017	14,531	3,119	2,371	4,063	N/A
9/30/2017	14,572	3,131	N/A	3,963	N/A
6/30/2017	14,382	3,063	N/A	3,883	N/A
3/31/2017	14,273	3,077	N/A	4,073	N/A
12/31/2016	14,142	3,050	N/A	3,840	N/A
9/30/2016	13,880	2,936	N/A	3,632	N/A
6/30/2016	14,012	2,929	N/A	3,248	N/A
3/31/2016	14,032	2,861	N/A	3,353	N/A
12/31/2015	14,002	2,823	N/A	3,339	N/A
9/30/2015	13,731	2,734	N/A	2,945	N/A
6/30/2015	13,393	2,630	N/A	3,308	N/A
3/31/2015	13,005	2,539	N/A	3,391	N/A
12/31/2014	12,459	2,526	N/A	4,525	N/A
9/30/2014	12,218	2,484	N/A	5,061	N/A
6/30/2014	11,970	2,413	N/A	4,791	N/A
3/31/2014	11,934	2,379	N/A	4,235	N/A
12/31/2013	11,746	2,200	N/A	2,599	N/A
9/30/2013	11,617	2,132	N/A	2,547	N/A
6/30/2013	11,519	2,085	N/A	2,531	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NSIS Nの予測収益成長率 (年間19.5% ) は貯蓄率 ( 7.7% ) を上回っています。

収益対市場: NSIS Nの収益 ( 19.5% ) はMX市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高成長収益: NSIS Nの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: NSIS Nの収益 ( 12.3% ) MX市場 ( 7% ) よりも速いペースで成長すると予測されています。

高い収益成長: NSIS Nの収益 ( 12.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NSIS Nの自己資本利益率は、3年後には低くなると予測されています ( 8.1 %)。

Novozymes 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Novonesis Provides Sales Guidance for the Year 2024

Novonesis Provides Earnings Guidance for the Year 2024

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘